Insider Trading Alert - GM, SLAB And BDX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

General Motors (GM) - FREE Research Report

Mulva James J, who is Director at General Motors, bought 28,343 shares at $35.28 on May 19, 2015. Following this transaction, the Director owned 28,343 shares meaning that the stake was boosted by 100% with the 28,343-share transaction.

The shares most recently traded at $34.84, down $0.44, or 1.26% since the insider transaction. Historical insider transactions for General Motors go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 73.4 million
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 73.4 million
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 73.4 million

The average volume for General Motors has been 14.7 million shares per day over the past 30 days. General Motors has a market cap of $56.3 billion and is part of the consumer goods sector and automotive industry. Shares are up 0.6% year-to-date as of the close of trading on Tuesday.

General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. It operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. The stock currently has a dividend yield of 4.11%. The company has a P/E ratio of 16.3. Currently, there are 8 analysts who rate General Motors a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GM - FREE

TheStreet Quant Ratings rates General Motors as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, impressive record of earnings per share growth, notable return on equity and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full General Motors Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Silicon Laboratories (SLAB) - FREE Research Report

Hoff Kurt W, who is Sr VP of Worldwide Sales at Silicon Laboratories, sold 665 shares at $51.46 on May 19, 2015. Following this transaction, the Sr VP of Worldwide Sales owned 49,243 shares meaning that the stake was reduced by 1.33% with the 665-share transaction.

The shares most recently traded at $51.58, up $0.12, or 0.23% since the insider transaction. Historical insider transactions for Silicon Laboratories go as follows:

  • 4-Week # shares bought: 1,400
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 1,400
  • 12-Week # shares sold: 12,322
  • 24-Week # shares bought: 1,400
  • 24-Week # shares sold: 40,322

The average volume for Silicon Laboratories has been 280,800 shares per day over the past 30 days. Silicon Laboratories has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 8.88% year-to-date as of the close of trading on Tuesday.

Silicon Laboratories Inc., a fabless semiconductor company, designs, develops, and markets mixed-signal analog intensive integrated circuits (ICs). The company has a P/E ratio of 62.8. Currently, there are 6 analysts who rate Silicon Laboratories a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLAB - FREE

TheStreet Quant Ratings rates Silicon Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Silicon Laboratories Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Becton Dickinson (BDX) - FREE Research Report

Scott Bertram L, who is Director at Becton Dickinson, sold 2,160 shares at $141.74 on May 19, 2015. Following this transaction, the Director owned 22,416 shares meaning that the stake was reduced by 8.79% with the 2,160-share transaction.

Mecklenburg Gary A, who is Director at Becton Dickinson, sold 2,160 shares at $141.60 on May 19, 2015. Following this transaction, the Director owned 20,965 shares meaning that the stake was reduced by 9.34% with the 2,160-share transaction.

The shares most recently traded at $141.65, up $0.05, or 0.04% since the insider transaction. Historical insider transactions for Becton Dickinson go as follows:

  • 4-Week # shares sold: 9,302
  • 12-Week # shares sold: 9,302
  • 24-Week # shares sold: 9,302

The average volume for Becton Dickinson has been 1.2 million shares per day over the past 30 days. Becton Dickinson has a market cap of $29.7 billion and is part of the health care sector and health services industry. Shares are up 1.62% year-to-date as of the close of trading on Tuesday.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The stock currently has a dividend yield of 1.69%. The company has a P/E ratio of 26.0. Currently, there are 11 analysts who rate Becton Dickinson a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BDX - FREE

TheStreet Quant Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks